Clinical Efficacy And Safety Of TACE/HAIC Combined With Radiotherapy,Targeted Therapy And Immunotherapy In Hepatocellular Carcinoma

Objectives:The aim of this study is to investigate the efficacy and safety of TACE/HAIC combined with radiotherapy,targeted therapy and immunotherapy in hepatocellular carcinoma,in order to provide an effective treatment strategy for improving the prognosis and prolonging the survival of patients with hepatocellular carcinoma.Methods:This study can be divided into two major parts;in the first part,25 patients with hepatocellular carcinoma from June 1,2019 to December 31,2022,who were seen at hospital according to the designed inclusion and exclusion criteria,were screened,and all of these patients received a combined treatment regimen of TACE/HAIC,radiotherapy,targeted therapy,and immunotherapy.General and clinical data of the patients were collected,including age,gender,number of tumors,maximum tumor diameter,history of hepatitis B/C,Child-Pugh classification,EOCG PS score,BCLC stage,portal vein tumor thrombus,extrahepatic metastasis,transhepatic arterial intervention modality,radiotherapy technique and dose,targeted immunotherapy regimen and cycle,and content and grading of adverse effects.In the second part,the collected materials were analyzed using SAS 9.4,with the primary observation endpoints of ORR and safety and the secondary observation endpoints of OS and PFS.Result:Under the RECIST Version 1.1 evaluation criteria,after four treatments,the patients achieved an objective response rate(ORR)of 36%for the primary observational endpoint,with 9 patients achieving PR(36%),10 patients SD(40%),and 6 patients PD(24%).Using the mRECIST criteria to evaluate tumor efficacy,patients achieved an objective response rate(ORR)of 72%for the primary endpoint,with 6 patients achieving CR(24%),12 patients achieving PR(48%),1 patient maintaining SD(4%),and 6 patients presenting with PD(24%).At a median follow-up of 15 months,the median PFS(mPFS)was 18 months and the median OS had not achieved.Conclusion:TACE/HAIC combined with radiotherapy,targeted therapy and immunotherapy can significantly improve the efficacy of patients with hepatocellular carcinoma,and the adverse events are within safe and controllable limits,and no adverse events of death have occurred.